First Round of Abstract Submission Ends: Dec 28, 2023
Extended Early Bird Ends: Apr 16, 2024

Plenary Speakers

Dr. Dmitry Gabrilovich
AstraZeneca, UK
Title: Myeloid cells as regulators of tumor progression and effects of cancer immunotherapy
Dmitry Gabrilovich, MD, Ph.D., is an Executive Director and Chief Scientist, Cancer Immunology, AstraZeneca. He studied dendritic cell (DC) biology under Dr. Stella C. Knight at the Imperial College of London in the UK and then was trained in cancer research at U.T. Southwestern Medical School and Vanderbilt University in the laboratory of Dr. D. Carbone. In mid-1990s his group demonstrated, that DCs in cancer were functionally impaired. They have described the first tumor-derived factor directly implicated in DC defects in cancer and suggested that myeloid progenitor cells were the main targets for this negative effect. His group implicated lipid accumulation as one of the mechanisms negatively regulating function of DCs in cancer. Dr. Gabrilovich, together with Dr. Bronte, had discovered cells that now called myeloid-derived suppressor cells (MDSC). His group characterized these cells, described number of molecular mechanisms regulating expansion and function of these cells. His group provided first evidence that MDSC can be therapeutically targeted in patients. Dr. Gabrilovich was involved in number of clinical trials testing the effect of cancer vaccines and small molecules and antibodies that target myeloid cells. Dr. Gabrilovich was Robert Rothman Endowed Chair in Cancer Research and Head, Section of Dendritic Cell Biology at H. Lee Moffitt Cancer Center and then Christopher M. Davis Professor in Cancer Research at the Wistar Institute in Philadelphia and Wistar Professor at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania. Dr. Gabrilovich is American Cancer Society Research Professor and during last 8 years is listed as one of the most highly cited researchers in the field of Immunology.
Prof. Zhinan Yin
Jinan University, China
Title: New Immune cell therapy platform: allogenic gamma delta T cells
Will update
Prof. Tatsuo Kawai
Harvard Medical School, USA
Title: Clinical Transplantation Tolerance: Changing Paradigm in Organ Transplantation
Dr. Tatsuo Kawai is a professor of surgery at Harvard Medical School and the A. Benedict Cosimi Chair in Transplant Surgery at Massachusetts General Hospital. He is also director of the Legorreta Center for Clinical Transplantation Tolerance.

His clinical and research interests are primarily focused on development of methods to induce immunological tolerance in organ transplantation. He was the first to report a consistent model for induction of renal allograft tolerance in nonhuman primates through a mixed chimerism approach. This and subsequent pre-clinical reports have extended this approach to the world’s first clinical trials for induction of renal allograft tolerance in HLA mismatched kidney transplantation. This is a seminal achievement of a clinical protocol leading to the first reproducibly successful induction of renal allograft tolerance in humans and was reported in the New England Journal of Medicine in 2008 and 2013. He was awarded the Martin Research Prize at MGH in 2009 and the New Key Opinion Leader Award by the Transplantation Society in 2010 for this work. Most recently, he was appointed an inaugural director of the MGH Legorreta Center for Clinical Transplantation Tolerance, which was built to become the world’s leading center dedicated to preventing organ rejection after transplant surgery without the use of lifelong immunosuppression.
Prof. Steven F. Ziegler
Benaroya Research Institute, USA
Title: Will update soon
Dr. Ziegler graduated with honors from the University of Michigan in 1979, and in 1984 received his PhD in molecular biology from UCLA. Following post-doctoral training at the University of Washington, Dr. Ziegler spent five years as a staff scientist at Immunex, followed by three years as the Director of Immunology/Molecular Biology at Darwin Molecular.

He joined the Benaroya Research Institute at Virginia Mason (BRI) as an Associate Member in 1997. He is currently Director of External Collaborations and a Member of the Center for Fundamental Immunology. He is also an Affiliate Professor in the Immunology Department, University of Washington School of Medicine.

Areas of Research

The projects in Dr. Ziegler’s laboratory are focused on the factors that control normal immune regulation, as well as those that contribute to disease development and progression. The laboratory is currently engaged in two areas of investigation: the role of Foxp3 and regulatory T cells in controlling immunity and autoimmune-type responses, and the role of the epithelial cytokines TSLP and IL-33 in responses to infection and allergen challenge of barrier tissues such as the respiratory and gastrointestinal systems. They have also found a novel role for TSLP in the regulation of tumor progression, and have established a program in tumor biology, including metastatic breast cancer and colon cancer.
Prof. Mandelboim Ofer
The Hebrew University Hadassha Medical School, Israel
Title: Activation of inhibitory receptors by pathoges and tumors
Prof. Mandelboim received his Ph.D. in Immunology from the Weizmann Institute of Science, followed by a post-doctorate fellowship at the Harvard Medical School. He then joined the Department of Immunology and Cancer Research at the Faculty of Medicine at the Hebrew University, to establish a laboratory of NK cell biology. To this date, Prof. Mandelboim published more than 180 scientific papers, participated in 3 EU consortium grants, in two Marie Curie student network grants, and won an ERC advanced grant. He obtained grants in a total sum of more than 15,000,000 Euro, received more than 20 awards, and supervised more than 50 Ph.D. students.
Prof. Guido Poli
Vita-Salute San Raffaele University, Italy
Title: Will update soon
Born in Verona, Italy in 1957; married to Elisa Vicenzi, two sons: Andrea and Marco


-1982. M.D. degree, University of Ferrara, Italy (full marks cum laude).
-1985. Specialist in Oncology, University of Ferrara, Italy (full marks cum laude).

Professional Career & Research Activities

-1983-1985. Post-graduate fellow, Laboratory of Human Immunology (Head: Alberto Mantovani), “Mario Negri” Institute for Pharmacological Research, Milano, Italy where he published some of the earliest papers on monocyte and NK cell defects in HIV infection.
-1986-1993. Visiting Scientist, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA (Head: Anthony S. Fauci) where he published several highly cited papers on the earliest in vitro models of reversible HIV-1 latency by cytokines.
-1994-to date. Head, AIDS Immunopathogenesis Unit (renamed “Human Immuno-Virology [H.I.V.] in 2021), San Raffaele Scientific Institute, Milano, Italy.
-Since 2002. Associate Professor of Pathology and Immunology, San Raffaele University School of Medicine, Milano, Italy (promoted to Full Professorship in 2016). He is currently Chairman of the Bachelor-equivalent Course of Biotechnological Research in Medicine.-Since 2020. President, “Patto Trasversale per la Scienza” Association (https://www.pattoperlascienza.it/)

To date, he has published 282 scientific papers (241 of which indexed by Scopus), mostly on the pathogenesis of HIV infection, cumulating ca. 11,474 citations, a cumulative impact factor of ca. 1,380 and an H-index of 58 (https://www.scopus.com/authid/detail.uri?authorId=7201724419)

He also co-edited two books:
-Elisa Vicenzi & Guido Poli, Editors. “Human Retroviruses. Methods and Protocols” – Springer Protocols, Humana Press, 2013. http://rd.springer.com/book/10.1007%2F978-1-62703-670-2
- Fabio Romerio, Elisa Vicenzi & Guido Poli, Editors. “HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure” – Springer Protocols, Humana Press, 2022. https://link.springer.com/book/10.1007/978-1-0716-1871-4

He is Associate Editor or Reviewer for several scientific journals and international funding agencies.

International Membership

Since 2011
-International AIDS Society (IAS): https://www.iasociety.org/guido-poli
-International Collaboration for the Genomics of HIV
Since 2017
-College of Reviewers, Canadian Institutes of Health Research
-Scientific Advisory Board of the Canadian HIV Cure Enterprise (CanCURE)

-NIH Award of Merit (1992)
-European Society for Clinical Investigations (ESCI) Award (1999)
Prof. Lorenzo Moretta
Pediatric Hospital Bambino Gesù, Italy
Title: Anti-tumor Innate immunity, with particular focus on mechanisms/cells involved in immunosuppression of NK, CAR-T and other effectors
Will update soon
Prof. Antonio Sica
University of Eastern Piedmont Amadeo Avogadro, Italy
Title: Will update soon
Will update soon
Prof. Jiri Mestecky
University of Alabama at Birmingham, USA
Title: Will update soon
Will update soon